Canadian Media Releases 2001

Novartis Canada Media Releases 2001

12/14/01	Important Public Warning - Recall of Transderm-Nitro® 0.4 - Lot S68000

12/10/01	Femara® (letrozole) Data Demonstrate Survival Advantage Compared to Tamoxifen in First-Line Hormonal Treatment of Postmenopausal Women with Advanced Breast Cancer

12/6/01	New England Journal of Medicine Study Demonstrates Important Role for Diovan® (valsartan) in Treatment of Heart Failure

12/05/01	Health Canada grants Priority Review to Novartis' Gleevec® in the treatment of malignant gastrointestinal stromal tumors (GIST)

10/04/01	Comtan® for Parkinson's Disease Now Available in Canada

09/22/01	Health Canada Approves Unique Leukemia Medication, Gleevec®, Following Priority Review

05/23/01	Femara Approved as First-Line Treatment of Advanced Breast Cancer Following Priority Review by Health Canada

03/19/01	Novartis Pharmaceuticals Canada Inc. Announces Long-Term Supply Agreement with Patheon Inc.

01/16/01	Alberta Celebrates Alzheimer Awareness Month this January with Announcement that New Treatment, Exelon®, is Now Covered on Provincial Drug Plan

DISCLAIMER FOR ARCHIVES
The information in our Media Release Archives was factually accurate on the date of publication. This information remains on our website for historical purposes only. Novartis Pharmaceuticals Canada Inc. assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon this information as current or accurate after their publication dates.